Abbott LaboratoriesABTRevenue: is the business selling more than it used to?
$44.3B+6% YoYFY 2025
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→Revenue reached $44.3B in 2025, compounding +1% a year since 2022 though the pace has cooled.
Source: SEC EDGAR (XBRL company facts) · as at 2026-03-31
Abbott LaboratoriesABTNet income: how much of that revenue becomes profit?
$6.5B−51% YoYFY 2025
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→Net income was $6.5B in 2025, compounding -2% a year over three years. Earnings per share moved -54% over the last twelve months. Trailing twelve-month profit stands at $6.3B.
Source: SEC EDGAR (XBRL company facts) · as at 2026-03-31
Abbott LaboratoriesABTHow fast is it growing, year by year?
+5.7%revenue growth, FY 2025
Off the axis: 2018 earnings +396.4% - rebounds off a collapsed prior year.
→Revenue grew +6% in 2025 against a five-year average of +6%. Earnings went the other way (-51%) even as sales grew, so margins compressed: costs rose faster than revenue. 2018's +396% earnings rebound off a collapsed base sits off the axis.
Source: SEC EDGAR (XBRL company facts) · as at 2026-03-31
Abbott LaboratoriesABTRevenue per share: is your slice growing as fast as the company?
$25.36revenue per share, FY 2025
◌ 2026 = trailing twelve months to the latest filed quarter (2026-03-31), not a full fiscal year
→Revenue per share reached $25.36 in 2025, compounding +1% a year - in line with ABT's own +1%, so the share count is not distorting your slice. Free cash flow per share stands at $4.23.
Source: SEC EDGAR (XBRL company facts) · as at 2026-03-31
Abbott LaboratoriesABTFree cash flow: what is left in real cash after everything?
$7.4B+16% YoYFY 2025
→Free cash flow was $7.4B in 2025, compounding -2% a year since 2022.
Source: SEC EDGAR (XBRL company facts) · as at 2026-03-31
Abbott LaboratoriesABTHow much of every sales dollar ends up as free cash?
◌ 2026 = trailing twelve months to the latest filed quarter, not a full fiscal year
→17 cents of every sales dollar became free cash in 2025, and it has held steady since 2022.
Source: SEC EDGAR (XBRL company facts) · as at 2026-03-31
Abbott LaboratoriesABTWhat does staying competitive cost, per dollar of sales?
◌ 2026 = trailing twelve months to the latest filed quarter (2026-03-31), not a full fiscal year
→The biggest claim on each sales dollar is research and development, at 7% of revenue (capital spending 5%, stock compensation 1%).
Source: SEC EDGAR (XBRL company facts) · as at 2026-03-31
Abbott LaboratoriesABTWhen sales grow, do profits grow faster?
→Operating profit outgrew revenue in 3 of the last 5 years, most recently +18% against +6%. Each additional dollar of sales is landing more profitably than the last - the definition of operating leverage.
Source: SEC EDGAR (XBRL company facts) · as at 2026-03-31
Abbott LaboratoriesABTMargins: of every $1 of sales, how much survives each cost layer?
◌ 2026 = trailing twelve months to the latest filed quarter (2026-03-31), not a full fiscal year
→Operating margin has held near 18% since 2022. After everything, 15 cents of each sales dollar reaches net profit. ABT doesn't tag a gross-profit line in its filings, so the chart starts at operating margin.
Source: SEC EDGAR (XBRL company facts) · as at 2026-03-31
Abbott LaboratoriesABTWhat does it earn on the money it uses?
◌ 2026 = trailing twelve months to the latest filed quarter (2026-03-31), not a full fiscal year
→ROE of 12% and ROCE of 11% sit close together, so the returns come from the business itself rather than from borrowing.
Source: SEC EDGAR (XBRL company facts) · as at 2026-03-31
Abbott LaboratoriesABTWhat has the market paid for ABT over time?
30.2xP/E today
◌ 2026 = at the latest close (2026-09-04), over the trailing twelve months; earlier years are annual averages
→At 30.2x earnings, the market is paying 11% less than ABT's own 11-year median of 33.8x. Pessimism is priced in - the question is whether it is deserved.
Source: SEC EDGAR (XBRL company facts) · as at 2026-03-31
Abbott LaboratoriesABTWhat cash return does the business throw off per dollar of market value?
3.9%FCF yield today
◌ 2026 = at the latest close (2026-09-04), over the trailing twelve months; earlier years are annual averages
→Every dollar of market value currently buys 3.9% of annual free cash flow, right at ABT's 11-year median of 3.7%.
Source: SEC EDGAR (XBRL company facts) · as at 2026-03-31
Abbott LaboratoriesABTCould it handle its debt if things went wrong?
→Debt of $34.0B sits against $6.8B of cash, or 0.7x shareholders' equity. Earnings cover the interest bill 14 times over, so the debt is comfortably serviced.
Source: SEC EDGAR (XBRL company facts) · as at 2026-03-31
Abbott LaboratoriesABTIs the company's own capital growing?
→The company's own capital grew from $38.6B in 2023 to $52.1B (+35%). The business is building book value rather than consuming it.
Source: SEC EDGAR (XBRL company facts) · as at 2026-03-31
Abbott LaboratoriesABTHow much goes back, and how much leaks out as stock comp?
→Shareholders received $893M in buybacks and $4.1B in dividends in 2025. Stock compensation issued $664M of new shares in the same year, offsetting 13% of that.
Source: SEC EDGAR (XBRL company facts) · as at 2026-03-31
Abbott LaboratoriesABTHow fast is your ownership being diluted - or concentrated?
→The share count shrank 0.0% in 2025, averaging 0.3% a year over three years. Buybacks are concentrating your ownership: the same business, split fewer ways.
Source: SEC EDGAR (XBRL company facts) · as at 2026-03-31
Abbott LaboratoriesABTIs the dividend cheque growing?
→The dividend per share reached $2.35 in 2025, compounding +10% a year since 2020.
Source: SEC EDGAR (XBRL company facts) · as at 2026-03-31
Abbott LaboratoriesABTCan it afford the dividend?
◌ 2026 = trailing twelve months to the latest filed quarter (2026-03-31), not a full fiscal year
→The dividend consumed 63% of profit and 56% of free cash flow in 2025. That leaves room to keep paying through a weak year.
Source: SEC EDGAR (XBRL company facts) · as at 2026-03-31
Abbott LaboratoriesABTDoes ABT earn more on its capital than that capital costs?
→ABT earns 11.5% on the capital it employs, comfortably above the 10% most investors treat as the cost of capital. It was 14.2% in 2022, so the trend is down, though the pace has cooled.
Source: SEC EDGAR (XBRL company facts) · as at 2026-03-31
Abbott LaboratoriesABTABT has issued or retired shares - did shareholders end up better off?
→ABT issued +12% more shares from 2011 to 2025, but revenue per share still rose +86%. The dilution bought more growth than it cost existing holders.
Source: SEC EDGAR (XBRL company facts) · as at 2026-03-31
Abbott LaboratoriesABTAre the people running it buying or selling?
→Insiders bought $1M and sold $47M on the open market, a net sale of $46M. A further 30 filings were grants, option exercises or tax withholding, which say nothing either way.
Source: SEC EDGAR (XBRL company facts) · as at 2026-03-31